Paul Loadman

Paul Loadman is Professor at the Institute of Cancer Therapeutics within the Faculty of Life Sciences at the University of Bradford, specializing in pharmacokinetics and tumor drug metabolism of anti-cancer drugs. With over 40 years of experience, his research spans drug delivery systems, prodrug design, and analytical techniques including HPLC and LC/MS/MS.

His research focuses on:

• Pharmacokinetics and tumor-selective drug activation
• Matrix metalloproteinase-targeted therapeutics
• Novel analytical methods for drug interaction studies
• Preclinical-to-clinical translation of anticancer agents

Recent publications demonstrate strong focus on tumor microenvironment-targeted therapies including FAP-activated prodrugs, hypoxia-responsive agents, and fatty acid interventions for cancer prevention. Article themes show increasing emphasis on precision drug delivery and biomarker-driven clinical trials.

Active collaborations include the seAFOod Polyp Prevention Trial analyzing bioactive lipid mediators, and consultancy for pharmaceutical companies on pharmacokinetic study design.